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4-O-methylhonokiol prevent cardiac hypertrophy via suppression of lipid
accumulation, oxidative stress and inﬂammation in obesity mice induced by
high fat diet
Zhiguo Zhang1,2, Shudong Wang1,2, Shanshan Zhou1,2, Xiaoqing Yan2, Yang Zheng1,
Yi Tan2, Lu Cai2, Young Heui Kim3
1Cardiovascular Center, the First Hospital of Jilin University, Changchun, China,
2KCHRI at the Department of Pediatrics, University of Louisville, KY, USA, 3Bioland
R&D Center, Cheonan, Chungnam, South Korea
Objectives: Obesity is associated with cardiac inﬂammation, oxidative stress,
apoptotic cell death, resulting in cardiac hypertrophy cardiac dysfunction. Magnolia
as a herbal material obtained from Magnolia ofﬁcinalis has been found to play an
important role in anti-inﬂammation, anti-oxidative stress, and anti-apoptosis. In our
previous study, we found that the extract of Magnolia (BL153) attenuated cardiac
lipid accumulation, inﬂammation, oxidative stress, apoptotic cell death and cardiac
hypertrophy in high-fat-diet (HFD) -induced obese mice. However, the extract
contains some toxic ingredients that may limit the use of the Magnolia extract. In the
present study, we investigated the preventive effect on of HFD-induced obesity-
associated insulin resistance, lipid accumulation and inﬂammation in the heart by
BL153 bioactive constituent, 4-O-methylhonokiol (MH), using BL153 as a
reference.
Methods: C57BL/6J mice, 8 weeks of age, were treated with vehicle, BL153
(5mg/kg), MH (0.5mg/kg) or MH (1.0mg/kg) by gavage daily, during 24weeks of
normal (10 kcal% fat) fat diet or HFD (60 kcal% fat) feeding. At the endpoint
blood glucose, glucose tolerance, plasma triglyceride and cardiac function were
assessed. Cardiac lipid accumulation was measured by Oil Red O staining.
Cardiac ﬁbrosis, inﬂammation, and oxidative damage were assessed by Western
blot.
Results: 0.5mg/kg MH treatment signiﬁcantly ameliorated insulin resistance with
slightly decreased of body weight gain induced by HFD feeding. MH signiﬁcantly
attenuated HFD-induced hypertriglyceridemia and hypercholesteremia. MH treat-
ments ameliorated cardiac hypertrophy. MH treatments also attenuated cardiac lipid
accumulation through inhibiting the expression of fatty acid translocase / D36 and
evaluating the expression of peroxisome proliferator-activated receptor g coactivator 1
a (PGC1a) and suppressed oxidative stress markers (malondialdehyde) by increasing
nuclear-factor-E2-related-factor-2 (Nrf2) and inﬂammation markers (tumor necrosis
factor-a and plasminogen activator inhibitor-1).
Conclusions: Our study indicated that MH ameliorated HFD associated cardiac hy-
pertrophy cardiac lipid accumulation, inﬂammation, oxidative stress via down-
regulation of CD36 and upregulation of PGC1a and Nrf2.
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Berberine decrease b-amyloid level in N2a-APP695 cells through PPAR-
gamma-IDE signaling pathway
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Objectives: The aim of this study was to determine the effect of berberine on
Ab1-40 and Ab1-42 in the extractcellular ﬂuid of mouse neuroblastoma N2A
Swedish mutant (APPsw) cells (N2a-APP695), a widely used AD model in
vitro. We also detected the transcriptional and translational regulation of IDE
and PPAR-gamma expression after the treatment of N2a-APP695 cells with
berberine.
Methods: We used different concentrations of berberine treated with N2a-APP695
cells, and then used the Ab ELISA KIT detected the concentrations of Ab1-40 and
Ab1-42, subsequently used Western Blotting and RT-PCR tested the amount of IDE
and PPAR-gamma in different groups.
Results: The result showed that berberine decreased the levels of Ab1-40 and Ab1-42
in a dose-dependent manner. Compared with the 0mM berberine group, 10mM
berberine groups Ab40 decreased 33.61  7.68% and Ab42 decreased 39.40 
1.32%. To illuminate the reasons of berberine decreasing the levels of Ab1-40 and
Ab1-42 in the extracellular ﬂuid of N2a-APP695, the regulation of berberine on
IDE was studied in vitro in N2a-APP695 cells. Results indicated that berberine can
up-regulate IDE protein in both dose-dependent and time-dependent in N2a-APP695
cells, and also up-regulated the IDE-mRNA. Subsequently the experimental result
showed that berberine can up-regulate the expression of PPAR-gamma in N2a-
APP695 cells. 10mM berberine increased the expression of PPAR-gamma by
46.380.39% as controlled with 0mM berberine.
Conclusions: These experiments describe that berberine through activating PPAR-
gamma pathway can up-regulate the protein expression of IDE and then promote the
degradation of Ab, thereby reducing the level of Ab in the extracellular medium of
N2a-APP695 cells.C66 JACC Vol 64/16/Suppl C j OctobGW25-e2285
S-Propargyl-cysteine (SPRC) diminishes mitochondrial dysfunctions in
heart failure
Wu Dan, Qingxun Hu, Yi Zhun Zhu
Department of Pharmacology and School of Pharmacy, Fudan University
Objectives: One of the important factors of heart failure (HF) is mitochondrial
dysfunction. Growing evidences indicate that damage of mitochondria causes mito-
chondrial pathway apoptosis and the loss of cardiomyocytes, which are signiﬁcant in
the process of HF. At the meantime, the injury of mitochondrial respiratory chain
results in a decrease of cellular ATP level in HF. Hydrogen sulﬁde (H2S) is the
third gasotransmitter, which presents a wide range of cell function in the body.
S-Propargyl-cysteine (SPRC) is water-soluble H2S endogenous donor which has
protective effect on acute myocardial infarction in rats. The aim of this study was to
investigate how SPRC diminishes mitochondrial dysfunctions in HF.
Methods: HF in C57BL/6 mice (male, 6-8 weeks old) was induced by Isoprenaline
(7.5 mg/kg), which was administered for 3 weeks, once a day by subcutaneous in-
jection. Hydrogen peroxide (H2O2) 200mM was used to induce Myocardial oxidative
damage in H9c2 cells. H&E stain and masson trichrome stain were used to determine
the histopathological change. Cell viability assay was used to determine the protective
effect of SPRC in vitro. Caspase activity assay was used to determine the apoptosis
level. Lipid peroxidation, antioxidant enzymes, ATP level, mitochondrial DJm
measurement and mitochondrial respiratory chain complexes (I-IV) measurement
were used to determine the mitochondrial function. Western blot was used to deter-
mine the expression levels of Bcl-2, Bax, pro-Caspase 3/9 and PKCε.
Results: H&E stain and masson trichrome stain showed a signiﬁcant loss of
myocardium and increased ﬁbrosis in isoproterenol group compared with the vehicle
group. After SPRC (10, 25 mg/kg) treatment, the level of myocardial ﬁbrosis was
signiﬁcantly reduced. SPRC (10 - 50 mM) were found to increase cell viability
signiﬁcantly, which reduced by H2O2 in H9c2 cells. SPRC (10, 25 mg/kg) signiﬁ-
cantly decreased the level of apoptosis in mice compared to the model group. The
same result was observed in SPRC (10 - 50 mM) treated H9c2 cells. The level of
mitochondrial glutathione (GSH) and superoxide dismutase (SOD) was recovered by
SPRC treatment and the content of mitochondrial lipid peroxidation (LPO) was
decreased compared with H2O2 group. The content of ATP and the activity of
mitochondrial respiratory chain complexes were signiﬁcantly increased in SPRC
treated grouped which were severely reduced in H2O2 group. The mitochondrial
membrane potential was signiﬁcantly reduced and the calcium swelling was markedly
decreased in the SPRC groups. SPRC induced translocation of PKCε to mitochondria,
which reduced by H2O2.
Conclusions: This study suggests the therapeutic ability of SPRC in HF through the
protective effect of mitochondrial dysfunction.
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Growth hormone releasing hormone agonist enhances cell survival and
anti-apoptosis of bone marrow derived mesenchymal stem cells via activating
STAT3 signaling pathway to promote angiogenesis of hindlimb ischemia
Xia xiangyang, Hong Yu
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Objectives: growth hormone releasing hormone (GHRH) is an endocrine hormone
produced by pituitary gland and stored and released to the circulatory system by
hypothalamus and GHRH receptor has been conﬁrmed to exist on cardiomyocytes and
mesenchymal stem cells to adjust the functions of these cells. The effectiveness of
MSC transplantation has been limited to a relative low level main by the restricted
survival rate after injection. As to an artiﬁcially synthesized polypeptide compound,
the GHRH analogue JI-34 is better at the stability and stimulating efﬁciency through by
less degradation compared with physiological GHRH. Therefore, to testify a newly use
of GHRH agonist JI-34 whether it can enhance the survival of MSC will be attractive.
Methods: the survival, viability, migration angiogenesis ability and anti-apoptosis rate
of MSC is compared between two groups of mice MSC pretreated with JI-34 or not.
CCK-8, transwell assay, Western blot, quantitive RT-PCR, tube formation assay and
TUNEL staining kit were used in this paper. In vivo study we revealed the angio-
genesis ability of pretreated MSC by cell injection into ischemic hindlimb of 6 weeks
old C57/BL6 mice.
Results: After JI-34 pretreatment for 24hours, MSC’s viability had increased by
23%0.5% compared with controls in normoxia condition and 26%1% in
hypoxia conditions (0.5% O2). Cell migration capacity can also be raised after
pretreatment of JI-34 in transwell chamber with a relatively increased 27%2%
migration rate in a 24hour’s assay with 10% gradient of Fetal Bovine Serum
(FBS). Similarly, the supernatants of MSC pretreated with JI-34 co-cultured
with Human Umbilical Vein Endothelial Cells (HUVEC) depicted a higher
possibility of tube formation with longer tube length (754mm37mm) than
control ones (580mm40mm) in each visual ﬁeld on the matrigel. RT-PCR and
Western Blot showed that a highly augment of pro-angiogenic factors of
VEGF-A and SDF-1 with 8 fold and 7.5 fold increase relating to control
respectively. All these effects can be blocked by adding the speciﬁc antagonist
of JI-34, MIA602 to shut down the beneﬁts of JI-349. western blot showed that
STAT3 and other signaling pathway molecules acted as the switch could be
activated in 10minutes and picked at 30minutes, stayed for about 2 hours then
gradually turned down to the normal level. By adding speciﬁc inhibitor ofer 16–19, 2014 j GW-ICC Abstracts/Basic and Translational Medicine
STAT3, these results could not be observed. In vivo results demonstrated that
after surgery of hindlimb ischemia, mice (n¼12) treated with JI-34 pretreated
MSC, MSC and PBS revealed a signiﬁcantly difference of limb recovery and
rebuildment of newly formed vessels. Ultrasound Doppler displayed that mice
injected with treated cells gained a better recovery of blood perfusion in day 3
after surgery and sustained to day14 than MSC and PBS group. Immunoﬂuo-
rescence of CD31, a-SMA, TUNEL and immunohistochemistry also supported
the results that treated with JI-34, MSC increased vascularation and angio-
genesis of mice hindlimb ischemia.
Conclusions: the agonist of GHRH can activate the receptor of MSC to enhance its
viability and paracrine effect through STAT3 signaling pathway to promote the
angiogenesis of ischemic hindlimb of mice.
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Targeted Delivery of Hydrogen Sulﬁde Using Ultrasound and Intravenous
Microbubbles Attenuates Myocardial Ischemia-reperfusion Injury
Gangbin Chen, Jianping Bin, Shengcun Guo, Chuanxi Zhang, Yongkang Lu,
Yan Wang, Shuxin Shen, Xinzhong Li, Juefei Wu
Cardiovascular Division, Nanfang Hospital, Southern Medical University,
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Objectives: Myocardial ischemia-reperfusion injury is a major cause of cardiac
damage following revascularization in acute myocardial infarction. Hydrogen Sulﬁde
(H2S) has emerged as a critical signaling molecule with a profound cardioprotective
effect. However, systemic delivery of H2S is hampered by cytotoxicity. We hypoth-
esized that intravenous administration of microbubbles encapsulating H2S gas com-
bined with ultrasound exposure permit safe and local release of H2S and attenuate
myocardial ischemic-reperfusion injury.
Methods: A 1:1 mixture of the H2S (4ml) and perﬂuorocarbons (4ml) was encap-
sulated into microbubbles (H2S-MB), while microbubbles containing 8ml of
perﬂuorocarbons (PESDA) served as control. Wistar rats were subjected to tempo-
rary ligation of the left coronary artery for 45min. H2S-MB or PESDA were
administered intravenously 5min prior to reperfusion for 10min with or without
ultrasound applied over the heart. H2S concentrations were measured in plasma and
tissue homogenate (heart, lung, kidney and brain) by methylene blue assay. Infarct
size was determined by evans blue and TTC staining. Serum levels of the cardiac-
speciﬁc isoform of troponin-I (cTnI) were assessed 4h after reperfusion. Left ven-
tricular structure and function was assessed by echocardiography 3 weeks after
reperfusion.
Results: Intravenous H2S-MB administration in combination with the ultrasound
exposure enhanced the concentrations of H2S in the myocardial and lung tissue
(P<0.05). Rats receiving H2S-MB and ultrasound representing a signiﬁcant reduction
in infarct size and serum levels of cTnI as compared with PESDA and ultrasound
treated rats (28.02.6% vs 44.64.5%, P¼0.005; 7.61.5 ng/ml vs 13.32.0 ng/ml,
P¼0.019, respectively). There were signiﬁcant differences in ejection fraction between
H2S-MB group and PESDA group both treated with ultrasound exposure (48.61.5%
vs 41.02.0%, P¼0.006). No signiﬁcant hemodynamic differences between H2S-MB
and PESDA were observed.
Conclusions: Targeted delivery of H2S using ultrasound and intravenous micro-
bubbles limits the extent of myocardial ischemia-reperfusion injury. This may provide
a noninvasive strategy for targeted delivery of a therapeutic gas to protect myocardial
injury from ischemia–reperfusion, avoiding systemic side effects.
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Vasomotor effect of salidroside on rat mesenteric artery and its regulatory
mechanisms
Sun Weiwei, Xu Peng, Cui Yingkai, Cao Xuebin
No.252 Hospital of PLA
Objectives: To observe vasomotor effect of salidroside (SAL) on rat mesenteric ar-
tery, and to explore its underlying regulatory mechanisms.
Methods: Tension was measured by DMT 610M system to evaluate the vasomotor
effect of SAL on rat endothelium-intact and endothelium-denuded mesenteric artery
rings. L-NAME, an inhibitor of nitric oxide synthase (NOS), indomethacin, a
Cyclooxygenase (COX) inhibitor, calcium deprivation and calcium addition were
used to illustrate the mechanisms of vasomotor effect of SAL.
Results: ① SAL (10-8mol/L - 10-4 mol/L) neither had signiﬁcant effect on mesenteric
artery rings keeping the basic state nor ones precontracted by KCl (610-2mol/L)
(P>0.05).② SAL relaxed endothelium-intact and endothelium-denuded mesenteric
artery precontracted by phenylephrine (210-6mol/L) in concentration-dependent
manner, while the vasodilation of endothelium-intact mesenteric artery was signiﬁ-
cantly stronger than that of endothelium-denuded one (P<0.01 in 10-5 mol/L SAL
and P<0.001 in 10-4 mol/L SAL). ③ Pretreatment with L-NAME (10-4mol/L), for
30min signiﬁcantly attenuated the vasodilation of endothelium-intact mesenteric
artery induced by SAL (P<0.01 in 10-5mol/L SAL), while pretreatment with indo-
methacin (10-4mol/L), for 30 min had no effect on the vasodilation of endothelium-
intact mesenteric artery induced by SAL (P>0.05). ④ With calcium deprivation and
calcium addition, SAL relaxed endothelium-denuded mesenteric artery precontracted
by phenylephrine (210-6mol/L) (P<0.01 in 10-5 mol/L SAL), while SAL had no
effect on the increasing tension of mesenteric artery induced by adding CaCl2
(P>0.05).JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/BConclusions: These results indicate that SAL has endothelium-dependent relax-
ation effect on rat mesenteric artery, which might be related to the endothelial
nitric oxide (NO) pathway and inhibiting release of intracelluar calcium of rat
mesenteric artery. However, this vasodilation effect of SAL is not associated
with voltage-dependent calcium channel, the COX pathway and inﬂux of
extracellular calcium.
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Change and trend of the reperfusion injury salvage kinase and mitochondrial
permeability transition pore after ischemic postconditioning in myocardial
ischemia-reperfusion in rats
Xiao Jun
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Objectives: To explore the dynamic variance of the reperfusion injury salvage kinase
and mitochondrial permeability transition pore after ischemic postconditioning in
myocardial ischemia-reperfusionon in rats.
Methods: Lewis rats were randomly assigned to a ischemia-reperfusion or ischemic
postconditioning or sham operation protocol. All groups except sham operation group
underwent myocardial ischemia obtained by ligating anterior descending (LAD)
branch for 30min, and followed by 3, 6, 12, 24-hour and 2, 4, 7-day reperfusion
respectively.In ischemic postconditioning group, three cycles of 10s reperfusion fol-
lowed by 10s LAD re-occlusion were applied during the ﬁrst min of reperfusion. the
expression of P-AKT and P-ERK1/2 protein were mearsured by western blot, and
Spectrophotometer was used to determined the opening of mPTP at the end of the
reperfusion respectively.
Results: Compared with sham operation group, the expression of P-AKT and
P-ERK1/2 protein and the opening of mPTP increased (P<0.01) in both ischemia-
reperfusion group and ischemic postconditioning group at 3, 6, 12, 24-hour and 2, 4,
7-day reperfusion. Compared with ischemia-reperfusion group, the expression of
P-AKT and P-ERK1/2 protein increased (P<0.05), the opening of mPTP decreased
(P<0.05) in ischemic postconditioning group. In both ischemia-reperfusion group and
ischemic postconditioning group, no change in the trend of the expression of P-AKT
and P-ERK1/2 protein and the opening of mPTP, and the peak-time of expression of
P-AKT and P-ERK1/2 protein and the trough-time of opening of mPTP happened at
24h reperfusion.
Conclusions: Ischemic postconditioning increases the expression of P-AKT and
P-ERK1/2 protein, decreases the opening of mPTP between 3 hours and 7 days after
the reperfusion followed myocardial ischemia in rats. However, ischemic post-
conditioning does not change the trend in the expression of P-AKT and P-ERK1/2
protein and the opening of mPTP in ischemia-reperfusionon rats.
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Electrophysiological study of the mechanism of action of the Traditional Chinese
Medicine compound TMYX on the spontaneous activity of cardiac pacemaker
cells
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Objectives: Traditional Chinese Medicine (TCM) is one of the oldest organized
healing systems in the human history. The TCM approach to the disease differs from
that of western medicine since it is based on the holistic view of both the diseased
state and the associated therapy; modern western medicine focusses instead on the
identiﬁcation and treatment of speciﬁc molecular causes. Both approaches have a
long history of proven results. We therefore started a collaborative project to
investigate the molecular effects of a TCM drug (Tong Mai Yang Xin, TMYX, Le
Ren Tang, China) which is indicated in the treatment of brady- and tachy-arrhyth-
mias. The speciﬁc aim was to investigate whether this drug acts on the sinoatrial
node (SAN).
Methods: Experiments were carried out in cells isolated from rabbit SAN. The
whole-cell patch-clamp technique was used to record the spontaneous activity of
SAN myocytes in the absence and in the presence of TMYX. Based on the in-vitro
toxicity MTT test carried out on a cardiac cell line (H9C2) and on pilot electro-
physiological experiments, we chose to investigate the action of the drug in the
concentration range 0.02-2 mg/ml. The drug was dissolved in dimethyl sulfoxide
(DMSO) and therefore an appropriate amount of DMSO was also added to the
control solution. Action Potentials (AP) were acquired from regularly beating
single cells or cell-aggregates and analyzed by a customized software. Group
comparisons were carried out by paired t-test statistic (statistical signiﬁcance at
P<0.05).
Results: Stable spontaneous APs were recorded from SAN cells/aggregates before
and during perfusion of TMYX. The parameters that describe the properties of each
AP cycle were the following: 1) AP Rate, Maximum Diastolic Potential (MDP), Early
Diastolic Depolarization (EDD), Take-Off Potential (TOP), AP Duration at 50% of
repolarization (APD50). Speciﬁc details are provided in (1).
When SAN cells were challenged with 3 different concentrations (0.02, 0.2, and
0.6 mg/ml) of TMYX we observed in all cases a signiﬁcant (P<0.05) dose-dependentasic and Translational Medicine C67
